BioNTech SE (BNTX) Receives a Hold from J.P. Morgan
In a report released yesterday, Cory Kasimov from J.P. Morgan maintained a Hold rating on BioNTech SE (BNTX). The company’s shares closed last Tuesday at $102.03.
According to TipRanks.com, Kasimov is a 5-star analyst with an average return of 22.5% and a 57.4% success rate. Kasimov covers the Healthcare sector, focusing on stocks such as Ultragenyx Pharmaceutical, Alexion Pharmaceuticals, and BioMarin Pharmaceutical.
Currently, the analyst consensus on BioNTech SE is a Moderate Buy with an average price target of $119.60, a 13.9% upside from current levels. In a report released yesterday, H.C. Wainwright also reiterated a Hold rating on the stock.
See today’s analyst top recommended stocks >>
Based on BioNTech SE’s latest earnings release for the quarter ending September 30, the company reported a quarterly revenue of $67.46 million and GAAP net loss of $210 million. In comparison, last year the company earned revenue of $28.66 million and had a GAAP net loss of $30.1 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
BioNTech SE focuses on the development of molecular immune therapies and biomarker-based diagnostic approaches. The firm develops and manufactures biomarker-based in vitro diagnostic devices (IVDD) and commercializes products. It offers drug discovery services for therapeutic areas including infectious diseases, allergies and autoimmune disorders. The company was founded by Christopher Huber, Özlem Türeci and Ugur Sahin in 2008 and is headquartered in Mainz, Germany.
Read More on BNTX: